Managing AML is pleased to present this complimentary CME/CPE/CNE webinar

New Advances in AML
Live Interactive Webcast Series

Thursday, July 2, 2020 – 3 PM EDT

Program Overview
In order to successfully develop targeted treatment plans and meet the clinical and disease needs of individual patients with AML, one must understand the key safety and efficacy data. This activity will focus on practical expert recommendations for optimizing the use of new and recently approved agents and regimens. Hear from three experts as they review the most appropriate therapeutic strategies for individual patients. You may submit questions about your practice and hear the experts respond during the live Q&A segment at the end of their presentation.

Target Audience
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives
Upon completion of this educational activity, participants should be able to:


Naval Daver, MD - Moderator
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jessica Altman, MD
Associate Professor
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Alexander Perl, MD
Associate Professor of Medicine
Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


15 minutes Frontline Treatment in AML: What You Need to Know to Choose the Best Option for Your Patient – Dr. Alexander Perl
15 minutes Treating Relapsed/Refractory AML: How to Choose the Right Options – Dr. Jessica Altman
15 minutes What's Next: New Data and Clinical Trials That Could Change Treatment – Dr. Naval Daver
15 minutes Audience Q&A


MediCom Worldwide, Inc. CME Credit
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
MediCom Worldwide, Inc. CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-024-L01-P . Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. Nursing Credit
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-024-122

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures
Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.

Dr. Jessica Altman has received honoraria related to formal advisory activities from AbbVie Inc., Agios, Daiichi Sankyo, Inc., and Theradex Systems, Inc., as well as speakers’ bureau activities from the France Foundation. She has also disclosed a financial relationship with GlycoMimetics, Inc. (Data Safety and Monitoring Committee).

Dr. Alexander Perl has received honoraria as a consultant from AbbVie Inc., Actinium Pharmaceuticals, Inc., Arog Pharmaceuticals, Inc., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., FORMA Therapeutics, Inc., and the Leukemia and Lymphoma Society, as well as formal advisory activities from Loxo Oncology and NewLink Genetics Corporation. He has received grant support related to research activities from AbbVie, Astellas, Bayer AG, Daiichi Sankyo, and Novartis AG.

Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Americans with Disabilities Act/Special Needs
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity.

CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 110 or

A confirmation screen will appear after your information is submitted. You will also receive an email registration confirmation within two business days.

If you do not receive the confirmation email, please check your spam or junk folder. You may also need to check with your network administrator.

Please complete the form below. Mandatory information is asterisked*.

First Name*
Last Name*
Your Degree*
Email Address*
Physicians Only NPI#
Physicians Only
Nurse, PAs, NPs Only SLN:
SLN State of Issue:
Mailing Address*
How many years have you been in clinical practice?
How many patients with acute myeloid leukemia do you personally see in a typical month?
Please rate your current level of confidence in your ability to determine prognosis based on the mutational profiling of a patient with AML.
How often do you currently monitor your patients taking an IDH inhibitor for symptoms of IDH-DS?
How often do you currently obtain a mutational profile on your AML patients prior to initiating treatment with a novel targeted agent?

Your information will never be sold, rented, leased or otherwise provided to any third party.

MediCom Worldwide, Inc.Provided by
Worldwide, Inc.

Supported by educational grants from Celgene Corporation, Helsinn, and Pfizer, Inc.